Bionano Genomics Reports 56% Jump in Rare Disease Research Publications
Event summary
- Bionano Genomics reported a 56% increase in Q1 2026 publications describing the utility of optical genome mapping (OGM) in rare diseases compared to Q1 2025.
- The number of samples analyzed in these studies rose by 225%, from 24 in Q1 2025 to 78 in Q1 2026.
- Publications highlight OGM's ability to resolve previously unresolved rare disease cases, serve as a gold standard for structural variant (SV) characterization, and complement sequencing for better SV sensitivity.
- Studies from institutions worldwide demonstrate OGM's role in identifying actionable disrupted genes across various rare diseases.
The big picture
Bionano Genomics' significant increase in research publications underscores the growing recognition of OGM as a critical tool in rare disease diagnostics. The technology's ability to resolve complex genomic variations missed by traditional methods positions it as a key player in the genomics market. As rare disease research continues to expand, OGM's role in providing actionable insights could drive further adoption and investment in the space.
What we're watching
- Adoption Pace
- The pace at which OGM is adopted as a standard tool in rare disease research will determine its long-term market penetration.
- Competitive Positioning
- Whether OGM can sustain its competitive edge against evolving sequencing technologies and other genomic analysis methods.
- Clinical Impact
- How the clinical utility of OGM in resolving rare disease cases translates into broader diagnostic and therapeutic applications.
Related topics